Federal Advocacy

A sweeping government funding package now before the U.S. Senate carries major implications for the life sciences sector - touching drug...

The recent White House announcement of “The Great Healthcare Plan” landed with familiar fanfare: bold promises to lower drug prices,...

A coalition of life sciences investors, Incubate, says capital is beginning to flow back into rare disease drug development, citing more than $1...

MichBio invites Michigan’s bio-industry community to join two upcoming federal legislative fly-ins in Washington, DC, offering direct...

In a detailed response to the White House Office of Science and Technology Policy (OSTP), the Biotechnology Innovation Organization (BIO) urged...

This month, the U.S. Food and Drug Administration (FDA) took a notable step toward modernizing oversight of digital health technologies -...

The U.S. Department of Health and Human Services (HHS) has formally lent its support to the Give Kids A Chance Act - landmark legislation...

In late December 2025, Congress completed action on the FY 2026 National Defense Authorization Act (NDAA)and with it, the...

Access to capital remains one of the most persistent challenges facing early-stage life sciences companies. On December 11, the U.S. House of...

Mergers and acquisitions (M&A) are a defining feature of the global life sciences industry. While often discussed in terms of market...

The U.S. Food and Drug Administration (FDA) has taken a noteworthy step toward modernizing how it collaborates with innovative technology...

A major bipartisan push to overhaul pharmacy benefit managers (PBMs) is back on the Senate agenda. On Dec. 4, Senate Finance Committee...